Reversion of multidrug resistance using nanoparticles in vitro: Influence of the nature of the polymer

• Published in: International journal of pharmaceutics Vol. 138; no. 2; pp. 237 - 246
• Main Authors: Némati, F., Dubernet, C., Fessi, H., Colin de Verdière, A., Poupon, M.F., Puisieux, F., Couvreur, P.
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier B.V 1996; Elsevier
• Subjects: Alginate; Antineoplastic agents; Biological and medical sciences; Doxorubicin; General aspects; Medical sciences; Multidrug resistance; Nanoparticles; P388; Pharmacology. Drug treatments; Polyalkylcyanoacrylate; Polylactide; Reversion; Nanoparticles; Reversion; Polylactide; P388; Multidrug resistance; Polyalkylcyanoacrylate; Alginate; Doxorubicin; Antineoplastic agent; Encapsulation; Control release polymer; P388-Leukemia; Alginates; In vitro; Lactic acid polymer; Alkyl acrylate(cyano) polymer; Preparation; Multiple resistance; Established cell line; Dosage form; Anthracyclins
• ISSN: 0378-5173; 1873-3476
• DOI: 10.1016/0378-5173(96)04559-0

Previous studies have already shown that polyalkylcyanoacrylate nanoparticles were able to overcome multidrug resistance in vitro. The study described in this paper investigated other types of nanoparticles, made of poly (lactic acid) PLA, poly (lactic-co-glycolic acid) PLGA and alginate, in order to determine if overcoming of resistance could be achieved with any nanoparticles independently of the nature of the polymer. In a first step, PLA and PLGA nanoparticles loaded with doxorubicin have been formulated, and the cytotoxicity of each preparation has been evaluated against P388 sensitive and resistant cells. Only polyalkylcyanoacrylate nanoparticles were effective: doxorubicin release experiments allowed to incriminate too rapid doxorubicin release in the case of PLA, PLGA and alginate nanoparticles to explain their lack of efficacy to overcome MDR.